Abstract
A 27-year-old woman, who had been diagnosed with pustular psoriasis at the age of 5 years, was started on infliximab (IFX) therapy when she was 26. Thereafter, she maintained clear skin with regard to the psoriasis area and the severity index. This therapy was discontinued after the 16th IFX administration because she was pregnant. Starting at the 20th gestational week, when numerous pustules and edematous erythema arose, she received GMA/GCAP twice a week for a total of 10 times. With this treatment, her severity score improved from 11 to 5. Because her symptoms relapsed after delivery at 32 gestational weeks, GMA/GCAP was given again without a good response. However, the eruptions promptly improved in response to re-administration of IFX with pretreatment. GMA/GCAP is considered to be relatively safe and effective for pregnant patients. Meanwhile, because the effects of IFX on pregnant women remain unclear, planned pregnancies recommended and an IFX therapy regimen should be considered.
